HIKAL LTD. - 524735 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Rajasekhar Reddy Designation :- Company Secretary and Compliance Officer HIKAL LTD. - 524735 - Closure of Trading Window
Intimation of closure of trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Update
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Earnings Call for Q3FY22 of Hikal Ltd
Conference Call with Hikal Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript. HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Update
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Hikal: More than financials, green integrity is crucial
We are entering increasing interest rate scenario. Liquidity is drying which simply means institutional fund flows would be much more selective and sensitive to quality aspect HIKAL LTD. - 524735 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations
Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of conference call to discuss the financial and operational performance for the quarter and nine months ended December 31, 2021 Q3FY22 Quarterly Result Announced for Hikal Ltd.
Pharmaceuticals firm Hikal declares Q3FY22 result: Revenue recorded an increase of 11% YoY Change in product mix and increase demand of key products Strong performance in Pharma own products and Crop Protection CDMO segments EBITDA increased to Rs 93 Crore, growth of 2% YoY EBITDA margin stood at 18.1% Positive impact of higher sales curbed by unfavorable product mix and increased utilities PAT was Rs. 45 Crore, YoY growth of 12% Increased operating profits, reduced interest cost and change in tax regime Lowered interest rates due to successful renegotiations The Company declared an interim dividend of 60% i.e., Rs. 1.20/share Hikal’s long term credit rating upgraded to A+ by ICRA Increased penetration in new geographies for key products Strong traction for the CDMO segment continues in both of our businesses due to the prevailing ‘China plus one’ sentiment Pharmaceuticals Recorded flat revenue at Rs. 268 Crore as compared to Q3 FY21 Stable sales corresponding with change in product mix EBIT stood at Rs 36 Crore, de-growth of 25% YoY Product mix change coupled with increased raw material and energy price Higher fixed cost in combination with flat revenues resulted in lower EBIT Several new customers acquired in different geographies Anti-diabetic portfolio of APIs for future is receiving healthy traction from customers Several new orders received from our key CDMO customers Process development has started for several active ingredients for the multi-year Animal health project with a global innovator Crop Protection - Performance Highlights Revenue stood at Rs. 246 Crores, recorded an increase of 27% YoY Increased sales volume of CDMO products Favorable price increases for certain products EBIT of Rs 38 Crore, growth of 22% YoY Efficient passthrough of costs to the customers Increase in new inquiries from CDMO customers in Q3 FY22 Demand continues to remain strong in domestic market Construction of new multipurpose facility for new products at Panoli is on track Result PDF
